Are you front of mind when pharma and biotech
outsource manufacturing and make procurement decisions?
It’s clear that drugs are becoming increasingly potent, a trend driven by novel potent therapeutics in oncology among other therapeutic areas.
However, drug developers have told us they lack visibility on which CMOs and equipment providers have the expertise and experience, as well as technology and facilities required to successfully manufacture highly potent APIs at the necessary yields.
Senior decision-makers at these leading companies will come together in June at the 8th Annual HPAPI Summit, actively seeking to collaborate with organizations that can help them take their potent compound manufacturing to the next level.
If you have capabilities that would benefit our audience in highly potent space, this meeting will provide a unique platform to showcase your solutions, generate new business leads and source opportunities for partnerships.